Company news

Mirum Pharmaceuticals, Inc. news in 2023

Mirum Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia

December 17, 2023

Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference

November 19, 2023

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

November 12, 2023

Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference

November 2, 2023

Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 1, 2023

Mirum Pharmaceuticals to Present New Data at The Liver Meeting®

October 29, 2023

Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023

October 26, 2023

Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

October 16, 2023

Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN

October 6, 2023

Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis

October 1, 2023

Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

September 25, 2023

Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference

September 20, 2023

Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer

September 10, 2023

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

September 4, 2023

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

September 4, 2023

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

August 2, 2023

Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023

July 26, 2023

Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome

July 24, 2023

Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals

July 16, 2023

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

July 16, 2023

Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress

June 22, 2023

Event-Free Survival Data from Mirum’s LIVMARLI Alagille Syndrome Program Published in Hepatology

June 13, 2023

Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress

June 6, 2023

Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting

May 18, 2023

Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis

May 17, 2023

Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting

May 16, 2023

Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study

May 10, 2023

Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 3, 2023

Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023

April 26, 2023

Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering

April 12, 2023

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

April 11, 2023

Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results

April 11, 2023

Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors

April 5, 2023

Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis

April 4, 2023

Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older

March 13, 2023

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

March 7, 2023

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023

February 28, 2023

Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

February 13, 2023

Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference

February 8, 2023

Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates

January 8, 2023

Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

January 2, 2023

Calls in 2023

Decks in 2023